Discover key insights from Embecta's Q2 2025 earnings call. Learn about revenue forecasts, cost-saving initiatives, product strategies & market dynamics.

Q2 2025 Earnings Conference Call May 9, 2025 8:00 AM ETCompany ParticipantsDev Kurdikar - President & CEOJake Elguicze ...

In a study published in eClinicalMedicine, researchers at the German Diabetes Center (DDZ) show that automated insulin ...

Insulet beat first-quarter profit estimates on Thursday, buoyed by strong demand for its wearable insulin pumps, sending shares up 7% in extended trading.

In a statement sent to Fierce Pharma Marketing, Cristian Azcarate, argenx’s VP of patient strategy, said the company’s work ...

Using the latest data and perspectives, an international expert panel releases updated recommendations for optimal insulin ...

The effects last around 14 to 24 hours and are at their most powerful around four to six hours after injection. NPH is administered with an insulin pen or syringe to the stomach, thighs ...

This may limit the access further as insulin delivery from pen devices is preferred by a huge majority of diabetics over vials injected with syringes, due to its accuracy, ease of dosing ...

These include: insulin vials and syringes (though rarely used now); re-useable insulin pens with insulin cartridges; and disposable prefilled pens. A major complication of poor injection technique ...

Booming sales of the Danish drugmaker’s new obesity and diabetes medicines, delivered in injection pens ... pens to glass vials and syringes. Pens are easier and more precise to use than syringes for ...

which can be delivered to patients through injections. This might lead to limited access as insulin delivery from pen devices is preferred by a huge majority of diabetics over vials injected with ...